• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

    1/5/26 9:05:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite
    • Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4
    • Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels. 1,2 Unlike traditional food logging apps that only give feedback after a meal is logged, Libre Assist1 helps people make informed mealtime decisions before they eat. Abbott is launching the new technology during CES 2026 in Las Vegas.

    Abbott's Libre Assist app feature uses a color-coded rating system – green for minor, yellow for moderate, and orange for major – to illustrate the food's potential glucose impact.

    For people living with diabetes, daily health decisions are constant, and food choices are among the most critical, especially for those managing their condition solely through lifestyle changes. The challenge is intensified by each person's unique response to food, making every meal decision complex.

    "The Libre Assist1 feature is a gamechanger for me," said Shirley Bovshow, who lives with Type 2 diabetes and is one of the first to try Abbott's new feature. "Traditional food logging apps left me guessing. With Libre Assist1 I can see how a meal might affect my glucose before I eat2—especially helpful when dining out or trying new foods. It gives me tips to reduce the glucose impact3 and my Libre 3 Plus sensor confirms the outcome afterward. The Libre app5 has become a go-to tool for me."

    Libre Assist1 uses generative AI to predict how a food choice may affect a person's glucose levels.2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions. After the meal, it leverages data from Abbott's leading Libre CGM systems sensors4 to confirm the actual impact.

    Libre Assist1 offers:

    • In-the-moment meal guidance: Before eating, users simply snap a photo or enter a text description of their food. The algorithm then identifies the ingredients and predicts the meal's potential glucose impact2 by displaying a color-coded rating: green for minor, yellow for moderate, and orange for major. Plus, it provides practical meal tips3 to help lower the potential glucose impact2 – like choosing plain Greek yogurt instead of flavored or eating leafy greens and proteins before starches.
    • Powerful CGM integration: After a meal, Libre Assist shows the individual's personal glucose data from their Libre CGM systems sensor to show how the meal actually affected their glucose. 1.2 This personalized feedback helps individuals understand their body's unique response to different food items, so they can make informed decisions in the future.

    "People living with diabetes need more than apps that just log food and fall short of helping them with meal decisions," said Marc Taub, vice president of technical operations for Abbott's diabetes care business. "That's why Abbott built Libre Assist1 – a free, and advanced predictive tool that delivers personalized meal guidance and works with our leading Libre technology to deliver real-time glucose insights. For the first time, people have smart, in-the-moment support right at their fingertips to make a confident choice every time they eat. 2,3"

    Libre Assist1 can be accessed within the Libre app5 by clicking on the Insights tab on the bottom navigation. There's nothing extra to sign up for – no monthly fees, no additional purchases, and no separate prescription required. To get started, individuals can download the Libre by Abbott app from the Apple App Store or Google Play Store.

    Abbott at CES 2026

    Visit Abbott at the Las Vegas Convention Center, Jan. 6–9, 2026, at CES Booth #8713 to learn more about Libre Assist1 feature and how it's shaping the future of health technology.

    About FreeStyle Libre:

    Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio4, which today is used by more than 7 million people across over 60 countries4. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries4.

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.

    Important Safety Information: Product for prescription only, for Important Safety Information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

    1 Libre Assist is a feature within Libre app that uses generative artificial intelligence to provide information on how foods could impact your glucose levels. Generative artificial intelligence may not always be accurate, and it should not be used to make treatment decisions.

    2 Predicted glucose impact is based on user-provided food data and may differ from actual impact, which depends on sensor readings and factors like activity, stress, medication, and alcohol. For personalized advice, consult your healthcare provider.

    3 Personalized meal guidance is based on food preference information inputted by the user.

    4 Data on File, Abbott Diabetes Care.

    5 The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.

     

    Abbott Logo (PRNewsfoto/Abbott)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbotts-new-libre-assist-app-feature-tackles-a-top-need-for-people-living-with-diabetes-in-the-moment-food-decisions-302651919.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abbott hosts conference call for fourth-quarter earnings

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    1/5/26 4:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

    Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every biteLibre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the million

    1/5/26 9:05:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

    Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib)Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythmsAbbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter procedure times and supports better recovery and long-term resultsABBOTT PARK, Ill., Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced the U.S. Food and Drug Administration (FDA) has approved th

    12/22/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/5/26 6:46:46 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Roman Michael F

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/5/26 6:26:09 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gonzalez Patricia Paola

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/5/26 6:15:45 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    Abbott Laboratories filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    12/12/25 4:10:48 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    11/21/25 4:06:09 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    11/20/25 7:37:40 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott hosts conference call for fourth-quarter earnings

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    1/5/26 4:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

    Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increaseABBOTT PARK, Ill., Oct. 15, 2025  /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2025. Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.Third-quarter GAAP diluted EPS of $0.94 and ad

    10/15/25 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care